In a study of durvalumab combined with paclitaxel, doxorubicin, cyclophosphamide, as well as other chemotherapeutic agents in triple-negative breast cancer, RNA and DNA sequencing technology indicated that patients with residual disease (RD) exhibited upregulated CCL-3 and CCL-5 compared with patients with complete response (CR). This evidence concerns the gene CCL5 and triple-negative breast carcinoma.